Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...

Enhertu has shown 'unprecedented' trial results, giving hope to mums like Maggie Ngatai.

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Among the first presentations at the European Society for Medical Oncology (ESMO) meeting that kicked off today, were results ...

WILMINGTON, Del. - AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's ENHERTU (fam-trastuzumab deruxtecan-nxki) has demonstrated a significant progression-free survival (PFS) rate in patients with ...

Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu ...

Daiichi Sankyo and AstraZeneca’s ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12 Largest prospective ...

Daiichi Sankyo and AstraZeneca’s ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12 Largest prospective trial of ...